Elan and Ingenium Pharmaceuticals announced today a strategic alliance for the development of therapeutics for pain management.
Elan and Ingenium will jointly fund a four-year research programme, estimated at $10 million, leading to the identification of clinical candidates.
Elan will market any products developed, and Ingenium has the option to maintain development and marketing rights on all products developed through the alliance.
